

# Internal and External Dosimetry Assessment Symposium



KEYNOTE PRESENTATION

## First-in-Human Trial of Oral Drug to Remove Radioactive Contamination

The National Institute of Allergy and Infectious Diseases, part of the National Institute of Health, is funding a first-in-human clinical trial of an experimental oral drug for removing radioactive contaminants from inside the body. Internal radioactive contamination occurs when radioactive elements enter the body through inhalation, ingestion, or absorption through the skin or open wounds. The drug trial is testing the safety, tolerability, and processing in the body of escalating doses of the investigational drug product, HOPO-14-1, in healthy adults.



REGISTER  
HERE

**October 26, 2023**

Bethesda North Marriott  
Hotel & Conference Center  
Rockville, Maryland

8:00 a.m. – 4:00 p.m. EDT

**Keynote Presentation**

Dr. David Cassatt  
National Institutes of Health

10:15–11:00 a.m. EDT

### The symposium will also feature the following topics:

- > Status of Veterinarian Release Activities
- > Update on CAUG and RAMP Dosimetry Codes
- > Using IMBA to Estimate Uptake from Excretion
- > Highlights from the UK VARSKIN User's Group
- > Development of Dose Coefficients for Discrete Radioactive Particles using VARSKIN+, IMBA, and PiMAL
- > Patient Release: Bremsstrahlung Emissions from Internal Beta Emitters
- > Current Dosimetry Issues from Australia
- > Extravasation Flow and Dosimetry Model